Avenue Biosciences

Avenue Biosciences develops protein engineering technology that optimizes N-terminal signal peptides to improve secretion yield and quality of therapeutic proteins. Its high-throughput screen tests libraries of thousands of signal peptide and protein variants in CHO cells, combining wet-lab chemistry, gene synthesis, NGS analysis and machine learning.

The company offers three screening packages (single-chain, two-chain and custom) to developers of therapeutic proteins, including antibodies, fusion proteins, cell and gene therapies, mRNA therapies and enzymes. The website describes a partner-based collaboration model that delivers validated candidates with a report, and a July 2026 research collaboration with Circio on protein secretion for gene therapy is listed.

The company is described as having a laboratory in Helsinki, Finland and an office in Menlo Park, California, and it states that its team is based in Helsinki and Palo Alto. A January 2026 announcement reports a $5.7M raise to scale the platform. The website lists the University of Helsinki as parent organization and states that the company is open to applications, with no specific open roles listed.

Product: High-throughput signal peptide screening services and a machine-learning-assisted protein engineering platform for improving secretion in CHO cell expression.